Laura Strong

ASCO's CancerLinQ bought by ConcertAI. The scale of the project relative to the type of organization was always interesting. prnewswire.com/news-releases/…

@JackWestMD @Summitplc Excited for your new adventure! 👏

🚨 Big changes afoot! I'm proud to announce that I've joined Summit Therapeutics (@Summitplc) as VP of Clinical Development! I look forward to my colleagues learning more about the company & ivonescimab. No more commentary from me on new data, but I'll contribute as I can.

Amy Kind from @uwsmph shares a new NIH study building on the Neighborhood Atlas & the exposome. Ambitious vision for the future! The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias reporter.nih.gov/search/IZz3Bh4… #wibiohealth23 @BioForward

Always fascinating to hear Amy Kind from @uwsmph talk about the exposome and the data available in the Neighborhood Atlas. neighborhoodatlas.medicine.wisc.edu #wibiohealth23 @BioForward

Great to see @BioForward highlighting the growth of the biohealth industry in Wisconsin at their conference today. A couple of quick examples from this morning from Arrowhead and Danaher. #wibiohealth23

@bradloncar @BiotechTVHQ I’m so excited for you Brad! Good luck, and I’ll be watching for BiotechTV.

I have no idea what direction this project will take over time. This summer is a pilot and your ideas are welcome. Hopefully @BiotechTVHQ will become a resource that brings to life the news, and where anyone can learn about biotech and science in general. Thanks for watching! 📺

If you’ve been following me, you know that I’ve been doing video interviews with biotech leaders on social media for years. Now I’m taking it to the next level. Launching today: BiotechTV.com @BiotechTVHQ

Commentary by @lisamjarvis on promising results from small #pancreaticcancer vaccine study led by Memorial Sloan Kettering oncologists who teamed up w/ BioNTech: 1 lesson is that it’s possible to create a mRNA vaccine quickly enough 2 make a difference bloomberg.com/opinion/articl…"Much like Moderna & Merck’s cancer vaccine, which recently generated excitement for its potential to prevent melanoma from returning, these shots are tailored to a patient’s own tumor. Memorial Sloan Kettering researchers sent samples to BioNTech in Germany, where the tumor was analyzed to determine which mutations might elicit a helpful immune response. The recipe for up to 20 of those proteins were encoded in a personalized mRNA vaccine that was mailed back to the oncologists. Technology — inexpensive and rapid genome sequencing, AI, and mRNA — made it possible for patients to get their first doses in about nine weeks after their surgery."

If you haven't seen DataChat in action recently, check out our new Overview video to see how we're making analytics available to everyone! This week we'll also share highlights from our newest release. hubs.li/Q01v2lQ10

Love the range of companies pitching at #PressureChamber by @MadisonBiz From yogurt chips to cargo bikes to software for better radiopharma therapy #ForwardFest @Fwdtech madisonbiz.com/pressure-chamb…

My first in real life life conference in a bit. Very happy to be at HIMSS22. Talking to people about analytics platforms, data science, etc.

My next chapter has begun, and I'm looking forward to sharing more!

Why has the global rapid test kit supply chain been overwhelmed two years into the pandemic? Poor planning, Omicron and stretched logistics are to blame on.ft.com/3IlM9gU @hannahkuchler @mroliverbarnes @edwardwhitenz

@michael_gilman Congratulations! I’m very excited to see how the programs develop. “Targeted RNA degradation” brings up fond memories of my RNase therapy days.

News, people. prnewswire.com/news-releases/…

I brought the cold temps from Wisconsin and my @Bucks shirt to watch the @nuggets play in Denver. Excited to watch Jokic play! 🏀

The clinical + regulatory team got to design & execute a study demonstrating the “overall usability of an at-home SARS-CoV-2 collection kit” & helped improve the Instructions for Use. That’s why this paper – and this team – is special to me. humanfactors.jmir.org/2021/4/e29234

But could people test at home to avoid spreading the disease? At that point nasal sample self-collection for testing wasn’t a reality, even for flu.But the groups running the Seattle Flu Study were sending kits to homes and getting them back by mail. ncbi.nlm.nih.gov/pmc/articles/P…

Short thread about gratitude & research. I’ve been proud of prior publications, but this one is pretty special to me. Rewind to the start of the pandemic, and the cadence of daily life is completely upended. There is nothing we can DO about it. But then… humanfactors.jmir.org/2021/4/e29234

This news made me do a double-take. In a merger of opposites, City of Hope to buy Cancer Treatment Centers of America for $390 million. With @angRchen. Yes, City of Hope is buying CTCA. statnews.com/2021/12/08/cit…